Search and analyze individual stocks with comprehensive metrics
Sudeep Pharma
Fundamental Score
Sudeep Pharma Share Price & Market Analysis
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SUDEEPPHRM across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Strong Return on Equity (32.77%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (35.65%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Consistent Growth Track Record (32.48% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (50.39% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.28)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (27.51x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 59.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Weak Earnings Growth (-35.52% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Very High P/E Ratio
Observation: Significant overvaluation risk present.
Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.
Loading Peer Comparison
Finding companies in the sector...
Financial Statements
Comprehensive financial data for Sudeep Pharma
About SUDEEPPHRM
Company Details
Market Information
Performance
SUDEEPPHRM Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of SUDEEPPHRM?
SUDEEPPHRM is currently trading at ₹728.20 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of SUDEEPPHRM shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.
What is the P/E ratio of SUDEEPPHRM and what does it mean?
SUDEEPPHRM has a P/E ratio of 59.31x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹59 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.
How is SUDEEPPHRM performing according to Bull Run's analysis?
SUDEEPPHRM has a Bull Run fundamental score of 45.4/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 32.77%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.
What sector and industry does SUDEEPPHRM belong to?
SUDEEPPHRM operates in the Pharmaceuticals industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Sudeep Pharma. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.
What is Return on Equity (ROE) and why is it important for SUDEEPPHRM?
SUDEEPPHRM has an ROE of 32.77%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Sudeep Pharma generates profits from shareholders' equity. An ROE of 33% means the company generates ₹33 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.
How is SUDEEPPHRM's debt-to-equity ratio and what does it indicate?
SUDEEPPHRM has a debt-to-equity ratio of 0.28, which indicates conservative financing with low financial risk. This means the company has ₹28 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.
What is SUDEEPPHRM's dividend yield and is it a good dividend stock?
SUDEEPPHRM offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.
How has SUDEEPPHRM grown over the past 5 years?
SUDEEPPHRM has achieved 5-year growth rates of: Sales Growth 32.48%, Profit Growth 50.39%, and EPS Growth -35.52%. This consistent double-digit growth indicates a strong business model and competitive positioning. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.
What is the promoter holding in SUDEEPPHRM and why does it matter?
Promoters hold 76.15% of SUDEEPPHRM shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: N/A%.
How does SUDEEPPHRM compare with its industry peers?
SUDEEPPHRM trades at P/E 59.31x vs industry average 31.77x, with ROE of 32.77% and ROCE of 35.65%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether SUDEEPPHRM is outperforming its competitive set in profitability, growth, and valuation metrics.
What is SUDEEPPHRM's market capitalization and what category does it fall into?
SUDEEPPHRM has a market capitalization of ₹8230 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.
What are the key financial ratios to consider for SUDEEPPHRM?
Key ratios for SUDEEPPHRM: ROE 32.77% (Excellent), ROCE 35.65%, P/E 59.31x, Debt-to-Equity 0.28, Interest Coverage 27.51x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.
How volatile is SUDEEPPHRM stock and what is its beta?
SUDEEPPHRM has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.
What is the 52-week high and low for SUDEEPPHRM?
SUDEEPPHRM has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹728.20, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.
What are the key risks associated with investing in SUDEEPPHRM?
Key risks for SUDEEPPHRM include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.28), and operational challenges. The stock has a Fundamental Score of 45.4/100, indicating higher risk requiring thorough due diligence. Sector-specific risks in Pharmaceuticals include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.
What is SUDEEPPHRM's operating profit margin and how has it trended?
SUDEEPPHRM has a 5-year average Operating Profit Margin (OPM) of N/A%, which suggests room for improvement in operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.
How is SUDEEPPHRM's quarterly performance in terms of sales and profit growth?
SUDEEPPHRM's recent quarterly performance shows YoY Sales Growth of N/A% and YoY Profit Growth of N/A%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.
What is the FII and DII holding pattern in SUDEEPPHRM?
SUDEEPPHRM has FII holding of 1.54% and DII holding of 14.76%, totaling 16.30% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.